-
1
-
-
47949086046
-
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
-
Gage BF, Eby C, Johnson JA et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3), 326-331 (2008).
-
(2008)
Clin. Pharmacol. Ther
, vol.84
, Issue.3
, pp. 326-331
-
-
Gage, B.F.1
Eby, C.2
Johnson, J.A.3
-
2
-
-
60849097257
-
Estimation of warfarin dose with clinical and pharmacogenetic data
-
Klein TE, Altman RB, Eriksson N. Estimation of warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009).
-
(2009)
N. Engl. J. Med
, vol.360
, pp. 753-764
-
-
Klein, T.E.1
Altman, R.B.2
Eriksson, N.3
-
3
-
-
42449136621
-
Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multiethnic population: Comparison with other equations
-
Wu AH, Wang P, Smith A. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multiethnic population: comparison with other equations. Pharmacogenomics 9(2), 169-178 (2008).
-
(2008)
Pharmacogenomics
, vol.9
, Issue.2
, pp. 169-178
-
-
Wu, A.H.1
Wang, P.2
Smith, A.3
-
4
-
-
56549125038
-
Pharmacogenetics of warfarin: Development of a dosing algorithm for Brazilian patients
-
Perini JA, Struchiner CJ, Silva-Assunção E. Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian patients. Clin. Pharmacol. Ther. 84, 722-728 (2008).
-
(2008)
Clin. Pharmacol. Ther
, vol.84
, pp. 722-728
-
-
Perini, J.A.1
Struchiner, C.J.2
Silva-Assunção, E.3
-
5
-
-
23044440450
-
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen
-
Sconce EA, Khan TI, Wynne HA. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333 (2005).
-
(2005)
Blood
, vol.106
, pp. 2329-2333
-
-
Sconce, E.A.1
Khan, T.I.2
Wynne, H.A.3
-
6
-
-
79151476272
-
Pharmacogenomics of warfarin dose requirements in Hispanics
-
Cavallari LH, Momary K, Patel SR, Shapiro NL, Nutescu E, Viana MAG. Pharmacogenomics of warfarin dose requirements in Hispanics. Blood Cells Mol. Dis 46, 147-150 (2011).
-
(2011)
Blood Cells Mol. Dis
, vol.46
, pp. 147-150
-
-
Cavallari, L.H.1
Momary, K.2
Patel, S.R.3
Shapiro, N.L.4
Nutescu, E.5
Mag, V.6
-
7
-
-
84857011893
-
Prediction of warfarin dose reductions in Puerto Rican patients based on combinatorial CYP2C9 and VKORC1 genotypes
-
Valentin II, Vazquez J, Rivera-Miranda G. Prediction of warfarin dose reductions in Puerto Rican patients based on combinatorial CYP2C9 and VKORC1 genotypes. Ann. Pharmacother. 46(2), 208-218 (2012).
-
(2012)
Ann. Pharmacother
, vol.46
, Issue.2
, pp. 208-218
-
-
Valentin, I.I.1
Vazquez, J.2
Rivera-Miranda, G.3
-
8
-
-
77951498679
-
Integration of genetic, clinical and INR data to refine warfarin dosing
-
Lenzini PA, Wadelius M, Kimmel S et al. Integration of genetic, clinical and INR data to refine warfarin dosing. Clin. Pharmacol. Ther. 87(5), 572-578 (2010).
-
(2010)
Clin. Pharmacol. Ther
, vol.87
, Issue.5
, pp. 572-578
-
-
Lenzini, P.A.1
Wadelius, M.2
Kimmel, S.3
-
9
-
-
33746853872
-
Pharmacogenetic P-450 screening using the Tag-It universal bead-based array platform
-
Wong SH, Linder MW, Valdes R (Eds) AAC Press, DC, USA, 363-386
-
Gordon J, Merante F, Weiss S, Zastawny R. Pharmacogenetic P-450 screening using the Tag-It universal bead-based array platform. In: Pharmacogenomics and Proteomics: Enabling the Practice of Personalized Medicine. Wong SH, Linder MW, Valdes R (Eds). AAC Press, DC, USA, 363-386 (2006).
-
(2006)
Pharmacogenomics and Proteomics: Enabling the Practice of Personalized Medicine
-
-
Gordon, J.1
Merante, F.2
Weiss, S.3
Zastawny, R.4
-
10
-
-
45149100367
-
High carrier prevalence of combinatorial CYP2C9 and VKORC1 genotypes affecting warfarin dosing
-
Ruaño G, Thompson PD, Villagra D et al High carrier prevalence of combinatorial CYP2C9 and VKORC1 genotypes affecting warfarin dosing Pers. Med. 2008 5 225-232.
-
(2008)
Pers. Med.
, vol.5
, pp. 225-232
-
-
Ruaño, G.1
Thompson, P.D.2
Villagra, D.3
-
11
-
-
66849126349
-
Physiogenomic analysis of the Puerto Rican population
-
Ruaño G, Duconge J, Windemuth A et al. Physiogenomic analysis of the Puerto Rican population. Pharmacogenomics 10(4), 565-577 (2009).
-
(2009)
Pharmacogenomics
, vol.10
, Issue.4
, pp. 565-577
-
-
Ruaño, G.1
Duconge, J.2
Windemuth, A.3
-
12
-
-
84861146025
-
Application of the Fst statistics to explore pharmacogenomic diversity in the Brazilian population
-
Suarez-Kurtz G, Pena SDJ, Hutz MH. Application of the Fst statistics to explore pharmacogenomic diversity in the Brazilian population. Pharmacogenomics 13(7), 771-778 (2012).
-
(2012)
Pharmacogenomics
, vol.13
, Issue.7
, pp. 771-778
-
-
Suarez-Kurtz, G.1
Pena, S.D.J.2
Hutz, M.H.3
-
13
-
-
10744228888
-
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
-
Rost S, Fregin A, Ivaskevicius V et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427(6974), 537-541 (2004).
-
(2004)
Nature
, vol.427
, Issue.6974
, pp. 537-541
-
-
Rost, S.1
Fregin, A.2
Ivaskevicius, V.3
-
15
-
-
21144448879
-
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
-
Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352(22), 2285-2293 (2005).
-
(2005)
N. Engl. J. Med
, vol.352
, Issue.22
, pp. 2285-2293
-
-
Rieder, M.J.1
Reiner, A.P.2
Gage, B.F.3
-
16
-
-
77954212927
-
CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies
-
Villagra D, Duconge J, Windemuth A. CYP2C9 and VKORC1 genotypes in Puerto Ricans: a case for admixture-matching in clinical pharmacogenetic studies. Clin. Chimica Acta 411, 1306-1311 (2010).
-
(2010)
Clin. Chimica Acta
, vol.411
, pp. 1306-1311
-
-
Villagra, D.1
Duconge, J.2
Windemuth, A.3
-
17
-
-
84857703472
-
Prediction of warfarin dose: Why when and how?
-
Eriksson N, Wadelius M. Prediction of warfarin dose: why, when and how? Pharmacogenomics 13(4), 429-440 (2012).
-
(2012)
Pharmacogenomics
, vol.13
, Issue.4
, pp. 429-440
-
-
Eriksson, N.1
Wadelius, M.2
-
18
-
-
77952495872
-
Implementing genotype-guided antithrombotic therapy
-
Seip RL, Duconge J, Ruaño G. Implementing genotype-guided antithrombotic therapy. Future Cardiol. 6, 409-424 (2010).
-
(2010)
Future Cardiol
, vol.6
, pp. 409-424
-
-
Seip, R.L.1
Duconge, J.2
Ruaño, G.3
-
19
-
-
58449087539
-
Pharmacogenomics of warfarin: Uncovering a piece of the warfarin mystery
-
Gulseth M, Grice G, Dager W. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery. Am. J. Health Syst. Pharm. 66, 123-133 (2009).
-
(2009)
Am. J. Health Syst. Pharm
, vol.66
, pp. 123-133
-
-
Gulseth, M.1
Grice, G.2
Dager, W.3
-
20
-
-
33947227273
-
Association of warfarin dose with genes involved in its action and metabolism
-
Wadelius M, Chen LY, Eriksson N et al. Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121(1), 23-34 (2007).
-
(2007)
Hum. Genet
, vol.121
, Issue.1
, pp. 23-34
-
-
Wadelius, M.1
Chen, L.Y.2
Eriksson, N.3
-
21
-
-
4143065736
-
Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype
-
Hillman MA, Wilke RA, Caldwell MD et al. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 14, 539-547 (2004).
-
(2004)
Pharmacogenetics
, vol.14
, pp. 539-547
-
-
Hillman, M.A.1
Wilke, R.A.2
Caldwell, M.D.3
-
22
-
-
31344451857
-
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans
-
Takahashi H, Wilkinson GR, Nutescu EA et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics 16(2), 101-110 (2006).
-
(2006)
Pharmacogenet. Genomics
, vol.16
, Issue.2
, pp. 101-110
-
-
Takahashi, H.1
Wilkinson, G.R.2
Nutescu, E.A.3
-
23
-
-
49949106034
-
Dosing algorithms to predict warfarin maintenance dose in Caucasians and African-Americans
-
Schelleman H, Chen J, Chen Z et al. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African-Americans. Clin. Pharmacol. Ther. 84(3), 332-339 (2008).
-
(2008)
Clin. Pharmacol. Ther
, vol.84
, Issue.3
, pp. 332-339
-
-
Schelleman, H.1
Chen, J.2
Chen, Z.3
-
24
-
-
70649111382
-
CYP2C9*8 is prevalent among African-Americans: Implications for pharmacogenetic dosing
-
Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics 10(8), 1243-1255 (2009).
-
(2009)
Pharmacogenomics
, vol.10
, Issue.8
, pp. 1243-1255
-
-
Scott, S.A.1
Jaremko, M.2
Lubitz, S.A.3
Kornreich, R.4
Halperin, J.L.5
Desnick, R.J.6
-
25
-
-
55449100859
-
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans
-
Limdi NA, Beasley TM, Crowley MR et al. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 9(10), 1445-1458 (2008).
-
(2008)
Pharmacogenomics
, vol.9
, Issue.10
, pp. 1445-1458
-
-
Limdi, N.A.1
Beasley, T.M.2
Crowley, M.R.3
-
26
-
-
24944503322
-
A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity
-
Yuan HY, Chen JJ, Lee MT et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet. 14(13), 1745-1751 (2005).
-
(2005)
Hum. Mol. Genet
, vol.14
, Issue.13
, pp. 1745-1751
-
-
Yuan, H.Y.1
Chen, J.J.2
Lee, M.T.3
-
27
-
-
34548060277
-
Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients
-
Nakai K, Tsuboi J, Okabayashi H et al. Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients. Pharmacogenomics 8(7), 713-719 (2007).
-
(2007)
Pharmacogenomics
, vol.8
, Issue.7
, pp. 713-719
-
-
Nakai, K.1
Tsuboi, J.2
Okabayashi, H.3
-
28
-
-
77949873283
-
Genetic and clinical predictors of warfarin dose requirements in African-Americans
-
Cavallari LH, Langaee TY, Momary KM et al. Genetic and clinical predictors of warfarin dose requirements in African-Americans. Clin. Pharmacol. Ther. 87(4), 459-464 (2010).
-
(2010)
Clin. Pharmacol. Ther
, vol.87
, Issue.4
, pp. 459-464
-
-
Cavallari, L.H.1
Langaee, T.Y.2
Momary, K.M.3
-
29
-
-
72849127064
-
Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients
-
Pautas E, Moreau C, Gouin-Thibault I et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin. Pharmacol. Ther. 87(1), 57-64 (2010).
-
(2010)
Clin. Pharmacol. Ther
, vol.87
, Issue.1
, pp. 57-64
-
-
Pautas, E.1
Moreau, C.2
Gouin-Thibault, I.3
-
30
-
-
34347403221
-
Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes
-
Zhu Y, Shennan M, Reynolds KK et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin. Chem. 53(7), 1199-1205 (2007).
-
(2007)
Clin. Chem
, vol.53
, Issue.7
, pp. 1199-1205
-
-
Zhu, Y.1
Shennan, M.2
Reynolds, K.K.3
-
31
-
-
25144502325
-
Association of vitamin K epoxide reductase complex 1. (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population
-
Veenstra DL, You JH, Rieder MJ et al. Association of vitamin K epoxide reductase complex 1. (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet. Genomics 15(10), 687-691 (2005).
-
(2005)
Pharmacogenet. Genomics
, vol.15
, Issue.10
, pp. 687-691
-
-
Veenstra, D.L.1
You, J.H.2
Rieder, M.J.3
-
32
-
-
33645849823
-
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements
-
Aquilante CL, Langaee TY, Lopez LM et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 79, 291-302 (2006).
-
(2006)
Clin. Pharmacol. Ther
, vol.79
, pp. 291-302
-
-
Aquilante, C.L.1
Langaee, T.Y.2
Lopez, L.M.3
-
33
-
-
11244332058
-
A polymorphism in the VKORC1 gene is associated with an inter-individual variability in the dose-anticoagulant effect of warfarin
-
D'Andrea G, D'Ambrosio RL, Di Perna P et al. A polymorphism in the VKORC1 gene is associated with an inter-individual variability in the dose-anticoagulant effect of warfarin. Blood 105(2), 645-649 (2005).
-
(2005)
Blood
, vol.105
, Issue.2
, pp. 645-649
-
-
D'Andrea, G.1
D'Ambrosio, R.L.2
Di Perna, P.3
-
34
-
-
4544288090
-
Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose
-
Zhao F. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin. Pharmacol. Ther. 76(3), 210-219 (2004).
-
(2004)
Clin. Pharmacol. Ther
, vol.76
, Issue.3
, pp. 210-219
-
-
Zhao, F.1
-
35
-
-
55449125520
-
Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics
-
Schelleman H, Limdi NA, Kimmel SE. Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics 9(9), 1331-1346 (2008).
-
(2008)
Pharmacogenomics
, vol.9
, Issue.9
, pp. 1331-1346
-
-
Schelleman, H.1
Limdi, N.A.2
Kimmel, S.E.3
-
37
-
-
23644437525
-
Common VKORC1 and GGCX polymorphisms associated with warfarin dose
-
Wadelius M, Chen LY, Downes K et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5, 262-270 (2005).
-
(2005)
Pharmacogenomics J
, vol.5
, pp. 262-270
-
-
Wadelius, M.1
Chen, L.Y.2
Downes, K.3
-
38
-
-
67149091240
-
Validation of clinical testing for warfarin sensitivity: Comparison of CYP2C9-VKORC1 genotyping assays and warfarin dosing algorithms
-
Langley MR, Booker JK, Evans JP, McLeod HL, Keck KE. Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin dosing algorithms. J. Mol. Diagn. 11, 216-225 (2009).
-
(2009)
J. Mol. Diagn
, vol.11
, pp. 216-225
-
-
Langley, M.R.1
Booker, J.K.2
Evans, J.P.3
McLeod, H.L.4
Keck, K.E.5
-
39
-
-
84866738499
-
Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): Rationale and study design
-
Do EJ, Lenzini P, Eby CS et al. Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J. 12(5), 417-424 (2012).
-
(2012)
Pharmacogenomics J
, vol.12
, Issue.5
, pp. 417-424
-
-
Do, E.J.1
Lenzini, P.2
Eby, C.S.3
-
40
-
-
70649084116
-
Genotype-guided dosing of coumarin derivatives: The European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design
-
van Schie RM, Wadelius MI, Kamali F et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 10(10), 1687-1695 (2009).
-
(2009)
Pharmacogenomics
, vol.10
, Issue.10
, pp. 1687-1695
-
-
Van Schie, R.M.1
Wadelius, M.I.2
Kamali, F.3
-
41
-
-
78349294600
-
Statistical design of personalized medicine interventions: The clarification of optimal anticoagulation through genetics (COAG) trial
-
French B, Joo J, Geller NL et al. Statistical design of personalized medicine interventions: the clarification of optimal anticoagulation through genetics (COAG) trial. Trials 11(1), 108. (2010).
-
(2010)
Trials
, vol.11
, Issue.1
, pp. 108
-
-
French, B.1
Joo, J.2
Geller, N.L.3
-
42
-
-
84863012482
-
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy
-
Horne BD, Lenzini PA, Wadelius M et al. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb. Haemost. 107, 232-240 (2012).
-
(2012)
Thromb. Haemost
, vol.107
, pp. 232-240
-
-
Horne, B.D.1
Lenzini, P.A.2
Wadelius, M.3
-
43
-
-
42349108153
-
Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients
-
Michaud V, Vanier MC, Brouillette D et al. Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients. Clin. Pharmacol. Ther. 83(5), 740-748 (2008).
-
(2008)
Clin. Pharmacol. Ther
, vol.83
, Issue.5
, pp. 740-748
-
-
Michaud, V.1
Vanier, M.C.2
Brouillette, D.3
-
44
-
-
80054989280
-
A proposal for an individualized pharmacogenetic-based warfarin initiation dose regimen for patients commencing anticoagulation therapy
-
Avery PJ, Jorgensen A, Hamberg AK, Wadelius M, Pirmohameh M, Kamali F. A proposal for an individualized pharmacogenetic-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. Clin. Pharmacol. Ther. 90(5), 701-706 (2011).
-
(2011)
Clin. Pharmacol. Ther
, vol.90
, Issue.5
, pp. 701-706
-
-
Avery, P.J.1
Jorgensen, A.2
Hamberg, A.K.3
Wadelius, M.4
Pirmohameh, M.5
Kamali, F.6
-
45
-
-
20144363204
-
Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma
-
Choudhry S, Ung N, Avila PC et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am. J. Respir. Crit. Care Med. 171, 563-570 (2005).
-
(2005)
Am. J. Respir. Crit. Care Med
, vol.171
, pp. 563-570
-
-
Choudhry, S.1
Ung, N.2
Avila, P.C.3
-
46
-
-
44949094303
-
Pharmacogenetic response to albuterol among asthmatics
-
Corvol H, Gonzalez-Burchard E. Pharmacogenetic response to albuterol among asthmatics Pharmacogenomics 9(5), 505-510 (2008).
-
(2008)
Pharmacogenomics
, vol.9
, Issue.5
, pp. 505-510
-
-
Corvol, H.1
Gonzalez-Burchard, E.2
|